Alder BioPharma (ALDR) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Leerink Partners Raises Price Target on Alder BioPharma (ALDR) to $62 Following 2Q15
August 6, 2015 10:03 AM EDTLeerink Partners reiterated an Outperform rating on Alder Biopharm (NASDAQ: ALDR), and raised the price target to $62.00 (from $40.00), following 2Q15 results. ALDR reported 2Q15 EPS of $(0.46) that was below consensus estimates of $(0.40).
Analyst Joseph Schwartz commented, "On Wednesday (8/5) after the close, ALDR... More
